For research use only. Not for therapeutic Use.
((addition))-SJ733 (Cat.No:I013048) is a novel antimalarial agent developed by St. Jude Children’s Research Hospital. It has been shown to be effective against multiple strains of Plasmodium falciparum, the parasite that causes the most severe form of malaria. The compound works by targeting a specific enzyme in the parasite’s metabolism, making it a promising candidate for the treatment of drug-resistant malaria.
| Catalog Number | I013048 |
| CAS Number | 1424799-20-1 |
| Molecular Formula | C₂₄H₁₆F₄N₄O₂ |
| Purity | ≥95% |
| Target | Na+/K+ ATPaseParasite |
| Solubility | DMSO |
| IUPAC Name | (3S,4S)-N-(3-cyano-4-fluorophenyl)-1-oxo-3-pyridin-3-yl-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinoline-4-carboxamide |
| InChI | InChI=1S/C24H16F4N4O2/c25-19-8-7-16(10-15(19)11-29)31-22(33)20-17-5-1-2-6-18(17)23(34)32(13-24(26,27)28)21(20)14-4-3-9-30-12-14/h1-10,12,20-21H,13H2,(H,31,33)/t20-,21+/m0/s1 |
| InChIKey | VKCPFWKTFZAOTO-LEWJYISDSA-N |
| SMILES | C1=CC=C2C(=C1)C(C(N(C2=O)CC(F)(F)F)C3=CN=CC=C3)C(=O)NC4=CC(=C(C=C4)F)C#N |
| Reference | [1]. Jiménez-Díaz MB, et al. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5455-62. |
